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ISSBACKGROUND PRKAG2 gene variants cause a syndrome characterized by cardiomyopathy, conduction disease, and
ventricular pre-excitation. Only a small number of cases have been reported to date, and the natural history of the
disease is poorly understood.
OBJECTIVES The aim of this study was to describe phenotype and natural history of PRKAG2 variants in a large
multicenter European cohort.
METHODS Clinical, electrocardiographic, and echocardiographic data from 90 subjects with PRKAG2 variants (53%men;
median age 33 years; interquartile range [IQR]: 15 to 50 years) recruited from 27 centers were retrospectively studied.
RESULTS At first evaluation, 93% of patients were in New York Heart Association functional class I or II. Maximum left
ventricular wall thickness was 18  8 mm, and left ventricular ejection fraction was 61  12%. Left ventricular hyper-
trophy (LVH) was present in 60 subjects (67%) at baseline. Thirty patients (33%) had ventricular pre-excitation or had
undergone accessory pathway ablation; 17 (19%) had pacemakers (median age at implantation 36 years; IQR: 27 to 46
years), and 16 (18%) had atrial fibrillation (median age 43 years; IQR: 31 to 54 years). After a median follow-up period of 6
years (IQR: 2.3 to 13.9 years), 71% of subjects had LVH, 29% had AF, 21% required de novo pacemakers (median age at
implantation 37 years; IQR: 29 to 48 years), 14% required admission for heart failure, 8% experienced sudden cardiac
death or equivalent, 4% required heart transplantation, and 13% died.
CONCLUSIONS PRKAG2 syndrome is a progressive cardiomyopathy characterized by high rates of atrial fibrillation,
conduction disease, advanced heart failure, and life-threatening arrhythmias. Classical features of pre-excitation and
severe LVH are not uniformly present, and diagnosis should be considered in patients with LVH who develop atrial
fibrillation or require permanent pacemakers at a young age. (J Am Coll Cardiol 2020;76:186–97)
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187AB BR E V I A T I O N S
AND ACRONYM S
ACMG = American College of
Medical Genetics and Genomics
AF = atrial fibrillation
HCM = hypertrophic
cardiomyopathy
HF = heart failure
HTx = heart transplantation
ICD = implantable
cardioverter-defibrillatorH ypertrophic cardiomyopathy (HCM) is apredominantly autosomal-dominant disor-der associated with increased morbidity
and mortality (1). It is characterized by increased car-
diac mass, as a result of cardiomyocyte hypertrophy
and fibrosis, and is caused mainly by genetic variants
in genes encoding sarcomeric proteins. However, 5%
to 10% of adult cases of HCM are caused by rare,
non-sarcomere-related genetic defects, including
inherited neuromuscular and metabolic diseases
such as PRKAG2 syndrome (PS) (2).SEE PAGE 198 IQR = interquartile range
LV = left ventricular
LVEF = left ventricular
ejection fraction
LVH = left ventricular
hypertrophy
MACE = major adverse cardiac
event(s)
MWT = maximal wall thickness
PPrV = probable pathogenic
rare variant
PS = PRKAG2 syndrome
SCD = sudden cardiac death
VUS = variant(s) of unknown
ficancePS is caused by genetic variants in the PRKAG2
gene that encodes the adenosine monophosphate–
activated protein kinase gamma 2 regulatory subunit
(3). In the heart, PRKAG2 variants result in glycogen
accumulation within cardiomyocytes and are classi-
cally associated with the triad of severe ventricular
hypertrophy, electrocardiographic pre-excitation,
and conduction system disease (4). Because of the
complex electrophysiological impact of the disease,
an incidence of premature (<40 years) sudden cardiac
death (SCD) as high as 20% has been suggested (5).
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clinical characteristics and natural history of
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METHODS
STUDY DESIGN AND COHORT COMPOSITION.
This was a multicenter, retrospective, longi-
tudinal cohort study consisting of probands
and relatives with PRKAG2 genetic variants
recruited from 27 European cardiomyopathy
centers (Supplemental Table 1). Baseline and
follow-up clinical data were collected at each
participating center.
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FIGURE 1 Typical Histological Findings in Patients With PRKAG2 Syndrome
(A,B) Hematoxylin-eosin staining displaying hypertrophied myocytes. Magnification 200 and 400. (C,D) Periodic acid Schiff (PAS) staining
positive for glycogen accumulation in cardiomyocyte vacuoles. Magnification 200 and 400. Yellow arrowheads indicate PASþ deposits,
corresponding to glycogen. Images courtesy of Dr. Clara Salas, Department of Pathology, Hospital Universitario Puerta de Hierro Majadahonda.
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Male 48 (53) 36 (56) 12 (46)
Age, yrs 33 (15–50) 37 (18–50) 18 (9-39)
Family history of SCD 35 (39) 24 (38) 11 (46)
Stroke 4 (5) 4 (6) 0 (0)
Myopathy 2 (2) 2 (3) 0 (0)
Syncope 28 (32) 24 (38) 4 (18)
Chest pain 15 (17) 10 (16) 5 (22)
Palpitations 41 (49) 31 (50) 10 (46)
CK, U/l 79 (56–117) 106 (2–365) 66 (2-130)
NYHA functional class III or IV 6 (7) 5 (8) 1 (5)*
NT-proBNP, pg/ml 120 (21–1200) 170 (37–2168) 47 (10-224)
Pre-excitation 30 (33) 30 (44) 0 (0)
QRS, ms 126  36 131  37 108  26
Atrial fibrillation 16 (18) 16 (25) 0 (0)
LVH on ECG 43 (49) 37 (64) 6 (38)
LV MWT, mm 18  8 20  8 10  2
LA diameter, mm 39  8 41  8 33  5
LVEF, % 61  12 60  13 66  8
PPrV 28 (31) 20 (31) 8 (31)
Values are n (%), median (interquartile range), or mean  SD. *Cardiogenic shock in a pre-term newborn due to
sepsis.
CK ¼ creatine kinase; ECG ¼ electrocardiography; LA ¼ left atrial; LV ¼ left ventricular; LVEF ¼ left ventricular
ejection fraction; LVH ¼ left ventricular hypertrophy; MWT ¼ maximal wall thickness; NT-proBNP ¼ N-terminal
pro–brain natriuretic peptide; NYHA ¼ New York Heart Association; PPrV ¼ probably pathogenic rare variant;
SCD ¼ sudden cardiac death.
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189variants (PPrVs) and considered causal of PS if they
were associated with classical phenotypic expression
of the disease and/or typical histological findings on
endomyocardial biopsy (Figure 1) and exhibited a
minor allele frequency of <1  104 in the ExAC
database (10). The complete list of genetic variants
with interpretations and genetic classification is
available in Supplemental Table 2.
CLINICAL EVALUATION AND FOLLOW-UP. Clinical
data and cardiac test results were extracted from
available hospital records. Patients were considered
clinically affected by PS if they had 1 or more of the
following: otherwise unexplained left ventricular
hypertrophy (LVH) (maximal left ventricular [LV]
thickness $13 mm), LV ejection fraction
(LVEF) <50%, advanced conduction disorders, sus-
tained ventricular tachycardia, supraventricular ar-
rhythmias (atrial fibrillation [AF] or atrial flutter or
supraventricular tachycardia), electrocardiographic
abnormalities (including pre-excitation, conduction
disease, and repolarization abnormalities), or skeletal
myopathy. Carriers of PRKAG2 variants with none of
these findings were considered nonaffected.
Standard 12-lead electrocardiographic recordings
at baseline and follow-up were examined. Ventricular
pre-excitation on electrocardiography was diagnosed
on the basis of a short PR interval (#120 ms) with a
widened QRS complex ($110 ms) or with an abnormal
delta wave; Wolff-Parkinson-White syndrome was
defined by the presence of pre-excitation associated with
supraventricular arrhythmia. Sokolov-Lyon index criteria
were used to evaluate LVH on electrocardiography.
Creatine kinase and N-terminal pro–brain natri-
uretic peptide levels at the baseline visit were recor-
ded when available.
Details of clinical events prior to first clinical con-
tact and during follow-up (including the timing of
events) were collected. Events were characterized as
follows: new-onset AF, de novo pacemaker implan-
tation, LV assist device implantation, heart trans-
plantation (HTx), sustained ventricular tachycardia,
successfully resuscitated ventricular fibrillation,
appropriate implantable cardioverter-defibrillator
(ICD) shock, SCD, and cardiac and all-cause mortal-
ity. SCD was defined as an unexpected death due to
cardiac causes occurring within 1 h of the onset of
symptoms. Hospitalizations for heart failure (HF)
were also registered. Major adverse cardiac events
(MACE) were defined as a composite of appropriate
ICD shock, aborted SCD, SCD, HTx, LV assist device
implantation, and pacemaker implantation.
STATISTICAL ANALYSIS. Results are presented as
mean  SD for continuous variables with normaldistributions, as median (interquartile range [IQR])
for continuous variables without normal distribu-
tions, and as number (percentage) for categorical
data. For statistical analysis, Student’s t-test and the
Mann-Whitney U nonparametric test were used in
2-group comparisons. The chi-square test or Fisher
exact test was used for categorical variables. The cu-
mulative probability of the occurrence of clinical
events was estimated by using the Kaplan-Meier
method, and factors were compared using the log-
rank (Mantel-Cox) method. Statistical analyses were
performed using SPSS Statistics version 20.0 (IBM,
Armonk, New York).
RESULTS
The study cohort comprised 90 subjects (53% men;
median age at first evaluation 33 years; IQR: 15 to 50
years) from 47 families (median subjects per family 3).
Forty-seven patients (52.2%) were probands and 43
(47.8%) were relatives. All but 2 patients were Cau-
casians of European ancestry. Most subjects (98%)
carried missense variants (Supplemental Table 2).
After a comprehensive analysis of the main genes
currently associated with HCM, no additional rare
variants were identified in any of the probands
included in our study. The 2 non-Caucasian patients
FIGURE 2 Flowchart of the Subjects Included in the Study
Last follow-up
Median follow-up 6 years
First evaluation






4 aborted SCD 32 PM13 HF26 AF
5 deaths
4 normal phenotype 
Clinical events and phenotype of subjects during the study. Affected patients were subjects with 1 or more of the following: unexplained left ventricular hypertrophy,
left ventricular ejection fraction <50%, advanced conduction disorders, sustained ventricular tachycardia, supraventricular arrhythmias, electrocardiographic abnor-
malities, or skeletal myopathy. AF ¼ atrial fibrillation; HF ¼ heart failure; HTx ¼ heart transplantation; PM ¼ pacemaker; SCD ¼ sudden cardiac death.
TABLE 2 Clinical, Electrocardiographic, and Echocardiographic








Male 48 (53) 38 (56) 10 (50)
Age, yrs 42 (25–58) 43 (31–59) 28 (14–44)
NYHA functional class III or IV 10 (11) 9 (13) 1 (5)
Atrial fibrillation 26 (29) 26 (39) 0 (0)
LV MWT, mm 17  7 19  7 10  3
LA diameter, mm 39  10 42  9 31  7
LVEF, % 59  13 57  13 68  7
LVEF <50% 10 (11) 10 (15) 0 (0)
Values are n (%), median (interquartile range), or mean  SD.
Abbreviations as in Table 1.
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190were men from Pakistan and India, respectively.
Neither of them showed pre-excitation on electro-
cardiography, and maximal wall thickness (MWT) was
15 and 18 mm, respectively. The patient from Pakistan
had a pacemaker implanted at 38 years of age because
of advanced atrioventricular block and carried a PPrV
(p.His401Asp) not described in ExAC or ClinVar. The
other patient carried a frameshift variant classified as
pathogenic (p.Leu352Lysfs*6).
CLINICAL CHARACTERISTICS. At first evaluation,
71% of the 90 subjects (n ¼ 64; 56% men; median age
37 years; IQR: 18 to 50 years) had evidence consistent
with the PS and were considered clinically affected;
the remaining 26 were considered nonaffected car-
riers (Table 1). Probands (n ¼ 47) had a median age of
40 years (IQR: 19 to 54 years), and 60% were men.
Their mean MWT was 20  8 mm, and 32% had
pre-excitation.
Patients with mild (MWT <15 mm) or normal
phenotype (n ¼ 33) carried PPrVs in 36% of cases,
compared with 28% of individuals with more severe
expression of disease (p ¼ 0.50). This group of pa-
tients with a milder phenotype were mostly relatives(n ¼ 24 [73%]) and had median age of 33 years (IQR: 13
to 52 years) (compared with a median age of 41 years
[IQR: 23 to 54 years] in the group with a more severe
phenotype; p ¼ 0.38).
Almost 40% of patients in the entire cohort (n ¼ 90)
reported a family history of SCD in a first-degree












































All Patients Affected Patients
Affected patients were subjects with 1 or more of the following: unexplained left ventricular hypertrophy, left ventricular ejection
fraction <50%, advanced conduction disorders, sustained ventricular tachycardia, supraventricular arrhythmias, electrocardiographic
abnormalities, or skeletal myopathy. Abbreviations as in Figure 2.
J A C C V O L . 7 6 , N O . 2 , 2 0 2 0 Lopez-Sainz et al.
J U L Y 1 4 , 2 0 2 0 : 1 8 6 – 9 7 Natural History of PRKAG2 Syndrome
191relative, 18% had either a history of or current AF, and
4% had had strokes (Table 1).
Most subjects (n ¼ 74 [82%]) were in sinus rhythm
on their first available electrocardiogram. Mean PR
interval duration was 120  49 ms, and 35 patients
(39%) had PR intervals shorter than 120 ms. Only 30
patients (33%) showed pre-excitation patterns, and 7
(8%) had undergone accessory pathway ablation
previously; 13% showed first-degree atrioventricular
block. Mean QRS interval duration was mildly pro-
longed (126  36 ms), and left or right bundle branch
block was common (19% and 13%, respectively). At
first evaluation, 17 patients (19%) already had per-
manent pacemakers implanted, and 3 subjects had
ICDs (including 1 for secondary prevention).
Symptoms of skeletal muscular involvement such
as proximal muscle weakness or myalgia were seldom
reported (2% of patients); 19 subjects (21%) had
increased creatine kinase levels (>90 U/l).
Most of the 64 affected subjects (93%) were in New
York Heart Association functional class I or II, and
only 4 (6%) had LVEFs <50%. Overall, 60 of the 64
affected individuals at baseline evaluation (94%; 55%
men; median age 37 years; IQR: 17 to 50 years) had
LVH, with mean MWT $13 mm, including 50 (83%;
60% men; median age 36 years; IQR: 19 to 50 years)
with LVH that was in the range of HCM
(MWT $15 mm, mean 20  8 mm). Mean LVEF inthese 50 subjects was 60  12%, and mean left atrial
diameter was 41  10 mm. None had LV outflow tract
obstruction >30 mm Hg or evidence of systolic ante-
rior movement of the mitral valve.
NATURAL HISTORY AND CLINICAL EVENTS. During
a median follow-up period of 6 years (IQR: 2.3 to 13.9
years), 4 of 26 initially unaffected subjects (15%)
developed LVH and AF; 2 had LVEFs in the
lower range of normality (50%) on their
last echocardiograms.
In the entire cohort (n ¼ 90), arrhythmic compli-
cations were common. Of note, 14% of subjects who
were in sinus rhythm at baseline evaluation devel-
oped AF, and the total prevalence of AF at the end of
follow-up in the entire cohort was 29% (n ¼ 26). Age
at AF onset was very young, with an average of 43 
16 years. Interestingly, 32% presented the first
episode before 35 years of age (median age 43 years,
IQR: 31 to 54 years).
Fifteen patients (21%) without conduction disease
at baseline required permanent pacemakers during
follow-up (median age at implantation 37 years; IQR:
29 to 48 years). The main indication was advanced
atrioventricular block in 8 subjects (53%). Notably, 2
subjects required pacemakers after accessory
pathway ablation. The total proportion of subjects
with pacemaker at the end of follow-up in the entire
cohort was 36% (32 of 90 subjects), with a mean age at











90 73 49 16 2
90 73 46 15 1
Survival Free of MACE + All-Cause Mortality
Survival Free of MACE + All-Cause Mortality + AF
Blue line indicates freedom of major adverse cardiac events (MACE) and death; red line indicates freedom of MACE, death, and atrial
fibrillation (AF). MACE include sudden cardiac death (SCD), aborted SCD, appropriate implantable cardioverter-defibrillator discharge, heart
failure hospitalization, heart transplantation, and pacemaker implantation.
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192implantation of 37  16 years (median 37 years; IQR:
28 to 48 years). Finally, a total of 19 patients (21%)
received ICDs during follow-up, including 4 for sec-
ondary prevention following SCD events.
Ten of 68 affected patients at last follow-up (15%)
had LVEFs <50%; 13 (19% of affected) were admitted
with HF (median age at first admission 49 years; IQR:
33 to 73 years), and 4 patients (6%) required HTx
(mean age 37  17 years).
Twelve subjects in the entire cohort (13%) died
during follow-up (median age 52 years; IQR: 35 to
60 years). Causes of death in the affected patients
included SCD in 3 (25%), end-stage HF in 2, and strokein 2. A total of 5 nonaffected subjects died (1 because
of sepsis and respiratory failure, unknown causes in
the other 4) (Figure 2).
Table 2 shows the clinical, electrocardiographic,
and echocardiographic parameters at last evaluation
in the entire cohort and in affected and unaffected
subjects. Event rates at the end of follow-up in the
entire cohort and in affected subjects are shown in
Figure 3. Median age free of MACE and death was 64
years (95% confidence interval: 53 to 75 years), and
median age free of MACE, death, and AF was 52 years
(95% confidence interval: 42.5 to 61.5 years) (Figure 4,
Central Illustration).
CENTRAL ILLUSTRATION Manifestations, Survival Curve Free of Major Adverse Cardiac Events and Death, and




















































53% males, age 33±21 years
• 64 Affected: 56% males, age 36±21 years
• 26 Nonaffected: 46% males, age 25±19 years
No pre-excitation
Pre-excitation
Maximal Left Ventricular Wall Thickness 
in Affected Patients (mm)
0













Maximal Left Ventricular Wall Thickness (mm)
8
10
63% of patients with left ventricular wall
thickness <20 mm
EVENTS AT END OF FOLLOW-UP (%)
0
Heart Transplant 4
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Major adverse cardiac events were a composite of appropriate implantable cardioverter-defibrillator shock, aborted sudden cardiac death (SCD), SCD, heart trans-
plantation, left ventricular assist device implantation, and pacemaker implantation. Affected patients were subjects with 1 or more of the following: unexplained left
ventricular hypertrophy, left ventricular ejection fraction <50%, advanced conduction disorders, sustained ventricular tachycardia, supraventricular arrhythmias,
electrocardiographic abnormalities, or skeletal myopathy.
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193We did not find differences in baseline character-
istics and events according to sex, except that women
exhibited shorter PR intervals (136  40 ms vs. 115 
30 ms; p ¼ 0.002) (Supplemental Table 3). However,
mean MWT at diagnosis was significantly increased
and LVEF at baseline significantly decreased in sub-
jects with MACE during follow-up (20  9 mm vs. 16 
7 mm [p ¼ 0.04] and 55  16% vs. 64  8% [p ¼ 0.01],
respectively). Pre-excitation was not associated with
MACE in our cohort, with similar baseline PR in-
tervals in patients with and without events (131 
63 mm vs. 115  43 mm; p ¼ 0.30).
Because 2 of the rare genetic variants
(p.Arg302Gln and p.Asn488Ile) were present in 44%
of the patients included in the cohort, we compared
subjects with these genetic variants with those with
other rare genetic variants (Table 3). The 32 subjects
who carried the p.Arg302Gln variant belong to 10different families from 6 different countries (Spain,
Italy, Israel, Denmark, Portugal, and the United
Kingdom), with a median of 3 subjects per family
(IQR: 1 to 4). The 7 subjects who carried the
p.Asn488Ile variant come from 2 different families
in the United Kingdom (1 with 1 subject and the
other with 6 subjects).
Patients with these 2 genetic variants exhibited
pre-excitation more frequently and had a lower
prevalence of syncope but otherwise showed a very
similar clinical profile. There were no differences in
cardiovascular event rates during follow-up, with the
exception of AF, which was more common in patients
with the most common 2 variants (Table 3).
At the end of follow-up, 76% of patients (68 of
90) had signs and symptoms of PS, but pene-
trance of PS was only 31% at 40 years of age or
less.






(n ¼ 51) p Value
Baseline characteristics
Males 22 (56) 26 (51) NS
Age, yrs 32 (15–44) 36 (14–50) NS
Family history of SCD 14/38 (36) 21/49 (43) NS
Stroke 1/38 (3) 3/49 (6) NS
Syncope 10/38 (20) 18/49 (47) 0.008
Chest pain 7/38 (18) 8/49 (16) NS
Palpitations 20/38 (53) 21/49 (46) NS
Affected 28 (72) 36 (71) NS
Myopathy 2 /39 (5) 0 (0) NS
CK level, U/l (range) 56 (13–81) 98 (76–134) NS
Pre-excitation 17/34 (50) 13/47 (28) 0.002
LVH on ECG 19/33 (58) 24/43 (56) NS
PR interval, ms 103  52 131  45 NS
LV MWT, mm 19  10 17  7 NS
LVEF, % 57  14 62  11 NS
LVEF <50% 5/37 (13) 5/44 (10) NS
Follow-up
Pacemaker implantation 15 (38) 17 (33) NS
Sudden cardiac death 3 (8) 0 (0) NS
Heart transplantation 1 (3) 3 (6) NS
Death 3 (8) 9 (18) NS
Heart failure hospitalization 4 (11) 9 (18) NS
Atrial fibrillation 17 (46) 9 (18) 0.009
Values are n (%), median (interquartile range), n/N (%), or mean  SD.
Abbreviations as in Table 1.
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194DISCUSSION
This study shows that patients with PRKAG2 genetic
variants have a poor prognosis with a high rate of
complications including juvenile onset of conduction
disease, advanced HF, and potentially lethal ar-
rhythmias (Central Illustration). The detailed pheno-
typic characterization of our cohort reveals that the
classical features of PS, such as pre-excitation and
severe LVH, are not uniformly present in affected
patients, while AF is particularly common and pre-
sents almost a decade earlier than in sarcomeric HCM;
unaffected subjects may develop a clinical phenotype
relatively late in life, although mean age at onset of
PS manifestations in affected subjects generally oc-
curs between the third and fifth decade of life.
PS is a rare disease that is mostly identified as a
phenocopy of HCM. Patients with clinical features of
PS were initially described in the second half of the
20th century, but it was not until 2001 that the
responsible gene was identified (3). Since then,
several case series and small patient cohorts
have been reported (5–8). Most underline the
classical triad of severe cardiac hypertrophy,electrocardiographic pre-excitation, and conduction
system disease. However, our findings show that the
PS phenotype is quite heterogeneous, ranging from
severe presentation in infancy to cases of late-onset
mild LVH (Figure 5). Similarly, although PS is clas-
sically associated with severe LVH, fewer than one-
half of the affected subjects in our cohort had
LVH $20 mm.
The prognosis of HCM phenocopies associated with
defects in glycogen metabolism is generally worse
than that of disease caused by sarcomeric protein
gene variants (5,11). Danon disease is an X-linked
disease in which hemizygous men do not have any
unaltered copy of the LAMP2 gene and have a worse
prognosis than women, who are heterozygotes for the
genetic defect (11). The prognosis of patients with
PRKAG2 genetic variants in our cohort was better
than in Danon disease, particularly for men (PS is an
autosomal-dominant disease, and no differences in
phenotype were observed related to sex), but still
poor compared with sarcomeric HCM (11,12).
Notably, patients with PS are burdened with a high
incidence of HF and sudden death. SCD occurred in 3
subjects, and 4 additional subjects received ICDs for
resuscitated SCD, for a total prevalence of SCD in the
entire cohort of 8% (9% if the patient with an ICD for
secondary prevention at baseline evaluation is
considered). Clinical characteristics of these patients
are shown in Supplemental Table 4.
The cause of SCD in patients with PS is likely to be
multifactorial, with advanced heart block (13) and
ventricular fibrillation due to rapid conduction
through accessory pathways (5) as possible triggers. It
has been speculated that in younger patients, SCD
might be secondary to the degeneration of rapid
supraventricular arrhythmias (14) and, in patients
older than 30 years, due to cardiac conduction system
disease and asystole (15). Because of the lack of
adequate patient cohorts with sufficient follow-up
data, risk stratification for SCD remains challenging
in PS, and the decision to implant an ICD in primary
prevention should be made on an individual basis. In
our cohort, the decision for prophylactic ICD im-
plantation at participating centers was made taking
into account phenotype and family history of SCD,
particularly in symptomatic patients with unex-
plained syncope.
A total of 4 patients required HTx and 2 died of
end-stage HF in our study (7% of the whole cohort,
8% of affected subjects), and 9 (13% of the affected
patients) were in New York Heart Association func-
tional class III or IV (Supplemental Table 4). Few
studies have reported data on HTx or advanced HF in
patients with PS (3,12,16), but comparing our data
FIGURE 5 Clinical Diversity of PRKAG2 Syndrome
(A,B) Electrocardiogram and 2-dimensional echocardiogram of a 51-year-old patient with a PRKAG2 p.Glu342Gln variant showing pre-
excitation and mild left ventricular hypertrophy. (C) Parasternal short-axis view of a 22-year-old man with the p.Arg302Gln PRKAG2 variant
and a more severe phenotype (septal thickness 35 mm). (D) Late gadolinium enhanced cardiac magnetic resonance image of the patient in C
11 years after first assessment showing severe fibrosis in the intraventricular septum.
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of HTx and HF death, respectively), it appears that
advanced HF complication rates are worse in patients
with PS than in other patients with HCM.
Considering global MACE, MWT and LVEF at
baseline proved to be prognostic markers. Both fea-
tures are also related to worse outcomes in patients
with HCM (17), but it is interesting to note that the
mean LVEF of patients with events was 55%, sug-
gesting that values at the lower limit of the normal
range could already have clinical implications.
Compared with previously published series
(5,6,13), our cohort displayed considerable genetic
heterogeneity, with a total of 26 rare unique genetic
variants, most of which were missense. A number of
the rare genetic variants included in our study do not
fulfil ACMG criteria for pathogenic or likely patho-
genic but were included on the basis of a classical PS
phenotype or typical histological findings and very
low minor allele frequency. Although still thestandard for genetic interpretation, the validity of
ACMG criteria in classifying some rare gene variants
in specific cardiovascular-related genes has been
questioned (18). ACMG or any other criteria for calling
the pathogenicity of gene variants should always be
considered in combination with expert review and
clinical judgment. Most of the patients with PPrVs in
our study had rare variants that had not been previ-
ously reported and that cosegregated with phenotype
in the families. The ACMG criteria for variant classi-
fication provide a framework for genetic variant
interpretation but might not be as useful in patients
with prominent characteristics linked to certain syn-
dromes, as happens in PS. The ACMG criteria would
probably need an adaptation for PS, as has
occurred already with FBN1 variants in Marfan’s
syndrome (19) or more recently with MYH7 in dilated
cardiomyopathy (20).
In our opinion, the diagnosis of PS should always
be made on the basis of genetic findings, but specific
TABLE 4 Clinical Characteristics and Events During Follow-Up in Patients
With Pathogenic or Likely Pathogenic Variants According to ACMG Criteria








(n ¼ 28) p Value
Male 34 (55) 15 (53) NS
Age at first evaluation, yrs 32 (14–49) 40 (17–53) NS
Family history of SCD 22 (35) 13 (46) NS
Stroke 4 (6) 0 (0) NS
Myopathy 2 (5) 0 (0) NS
Syncope 20 (32) 8 (29) NS
Chest pain 13 (21) 2 (32) NS
Palpitations 32 (52) 9 (58) NS
Pre-excitation 21 (34) 9 (32) NS
Atrial fibrillation 11 (18) 5 (18) NS
LVH in ECG 30 (48) 13 (46) NS
PR interval, ms 111  47 139  51 NS
LVEF, % 62  11 57  14 NS
LV MWT, mm 18  9 16  6 NS
Follow-up
Pacemaker implantation 23 (37) 9 (32) NS
Sudden cardiac death 2 (3) 1 (4) NS
Heart transplantation 3 (5) 1 (4) NS
Death 8 (13) 4 (14) NS
Heart failure hospitalization 8 (13) 5 (18) NS
Atrial fibrillation 20 (32) 6 (21) NS
Values are n (%), median (interquartile range), or mean  SD.
Abbreviations as in Table 1.
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196clinical characteristics and positive cosegregation in
the family should have a strong role in interpreting
variants of unknown significance (VUS) found in the
PRKAG2 gene. Moreover, when interpreting a
PRKAG2 VUS, it is important to consider the patient’s
clinical context. Incidental findings of VUS in unaf-
fected patients without family histories of LVH, con-
duction disease, or atrial arrhythmia and VUS in
patients with other phenotypes should not be
considered disease-causing variants. In any case,
longitudinal follow-up is highly recommended in
these patients in order to monitor the phenotypic
expression of PS and enable possible variant
reclassification.
In this regard, we are confident that the variants
classified as PPrVs in our study represent PS-causing
variants. In fact, clinical characteristics and event
rates between patients with pathogenic or likely
pathogenic rare genetic variants and those with PPrVs
did not differ (Table 4).
PS might be a suitable candidate disease for enzy-
matic replacement therapy or for a gene therapy
approach, as in other lysosomal storage HCMphenocopies also caused by enzymatic defects. Fabry
disease and Pompe disease already have approved
enzyme replacement therapies (21), and gene therapy
clinical trials are currently being conducted in Danon
disease (NCT03882437) and Fabry disease
(NCT04040049). In this regard, our study would be
useful in designing appropriate clinical trials for PS in
the future.
Although there is no specific treatment for PS yet,
this study shows that lifelong follow-up of genetic
carriers is necessary, considering the high incidence
rate of cardiovascular events. In our study, 15% of
subjects who were unaffected at baseline went on to
develop signs of the disease during a median follow-
up period of just 2.8 years. Some developed sub-
stantial cardiac involvement and all had AF, high-
lighting the need for regular surveillance with
ambulatory electrocardiography. Furthermore,
frequent ambulatory electrocardiography should also
be recommended in affected patients given the high
rate of atrial arrhythmia and conduction disorders
found in this study.
STUDY LIMITATIONS. The study was not designed to
evaluate treatment effects. Causes of death were not
available in all nonaffected genetic carriers. The
study was subject to selection and referral bias, as the
participating centers are all specialized cardiomyop-
athy centers. Furthermore, even though this cohort is
the largest PS cohort published to date, given the
rarity of this disease, the reduced number of subjects
included limits the possibility of identifying prog-
nostic factors.
CONCLUSIONS
PS is a severe progressive cardiac disease character-
ized by a high rate of complications, including atrial
arrhythmias, conduction disease, advanced HF, and
SCD at a young age. Affected patients should be
closely monitored to facilitate early detection of
arrhythmia and conduction problems. PS should be
considered in patients with LVH who develop AF or
require permanent pacemakers at a young age. Early
recognition is important to allow prompt identifica-
tion and appropriate management of genetic carriers.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Variants
of the PRKAG2 gene cause a syndrome of cardiac glyco-
genosis that is characterized by progressive cardiomyop-
athy associated with a high incidence of heart failure, AF,
conduction system disease, and life-threatening arrhyth-
mias. The clinical characteristics are heterogeneous and
the classical findings of pre-excitation and severe LVH are
not uniformly present, but the diagnosis should be
considered in young patients with LVH who develop AF or
require pacemaker implantation.
TRANSLATIONAL OUTLOOK: Because penetrance is
incomplete and expressivity variable, further studies
are needed to identify the factors causing some indi-
viduals with PRKAG2 syndrome to experience cardiac
events, specifically arrhythmic complications. In the
future, enzyme replacement therapy may become
feasible, but efficacy and safety would require valida-
tion in clinical trials.
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